Sign in
CompletedPhase 2

Personalized Immunotherapy in Sepsis

Key facts

Who runs it
Hellenic Institute for the Study of Sepsis
Where
Germany, Greece, Italy, Netherlands, Romania, and Switzerland35 sites in 6 countriesChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
280 people enrolled
Started
29 Jul 2021
Ended
27 Apr 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Anakinra or rhIFNγ
  • Placebo
Record updated
19 March 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Age equal to or above 18 years
  • Both genders
  • In case of women, unwillingness to become pregnant during the study period
  • Written informed consent provided by the patient or by one first-degree relative/spouse in case of patients unable to consent
  • Community-acquired pneumonia (CAP) or hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) or primary bacteremia (BSI)
  • Sepsis defined by the Sepsis-3 definitions. More precisely, sepsis is defined as the presence of total SOFA (sequential organ failure assessment score) equal to 2 or more for patients who are admitted with infection at the emergency department OR as any increase of admission SOFA by 2 or more points for patients already hospitalized
  • Patients with signs of fulminant hyper-inflammation or sepsis-associated immunoparalysis as defined by ferritin and Quantibrite. Since the state of hyper-inflammation is considered more life-threatening than the state of immunoparalysis, patients with lab findings of both immune states are allocated to treatment targeting hyper-inflammation. It is explicitly stated that patients diagnosed with novel Coronavirus-2 infection (COVID-19) may participate only in the fulminant hyper-inflammation arm
  • Time from classification into sepsis by the Sepsis-3 definitions and start of blind intervention less than 72 hours

Who cannot take part

  • Oral or intravenous intake of corticosteroids at a daily dose equal or greater than 0.4 mg/kg prednisone or greater the last 15 days
  • Acute pyelonephritis or intraabdominal infection, meningitis or skin infection
  • Any stage IV malignancy
  • In the case of BSI, patients with blood cultures growing coagulase-negative staphylococci or skin commensals or catheter-related infections cannot be enrolled
  • Active tuberculosis (TB) as defined by the co-administration of drugs for the treatment of TB
  • Infection by the human immunodeficiency virus (HIV)
  • Medical history of systemic lupus erythematosus
  • Medical history of multiple sclerosis or any other demyelinating disorder
  • Neutropenia defined as an absolute neutrophil count lower than 1,500/mm3
  • Age below 18 years
  • Denial for written informed consent
  • Any 'do not resuscitate' decision in the hospital
  • Any primary immunodeficiency
  • Any anti-cytokine biological treatment the last one month
  • Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study

This trial has no sites in United States.

It has sites in 6 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Αim of ImmunoSep is to assess whether personalized adjunctive immunotherapy directed against a state of either fulminant hyper-inflammation or immunoparalysis is able to change sepsis outcomes. Patients will be selected by a panel of biomarkers and laboratory findings and will be allocated to placebo or immunotherapy treatment according to their needs.

The 2 groups in the trial

  • Standard of carePlacebo, for comparison

    Patients will receive the standard type of treatment decided by the attending physicians. They will also receive 20ml (10ml for patients with creatinine clearance lower than 30ml/min) intravenous (IV) 0.9% saline (N/S) three times daily (every eight hours) for 15 days and 0.5 ml subcutaneous (sc) 1ml 0.9% N/S every other day for a total of 15 days.

    Treatment: Placebo

  • ImmunotherapyTreatment being tested

    Patients will receive the standard type of treatment decided by the attending physicians. They will also receive IV anakinra 200 mg three times daily (every eight hours) or sc rhIFNγ 100 μg once every other day. More precisely, patients randomized for hyper-inflammation will receive anakinra three times daily (every eight hours) for 15 days and sc 0.5 ml N/S 0.9% every other day for 15 days. Patients having immunoparalysis will receive IV 20 ml N/S 0.9% (10ml for patients with creatinine clearance lower than 30ml/min) three times daily (every eight hours) for 15 days and sc rhIFNγ every other day for 15 days. Especially for patients with creatinine clearance lower than 30 ml/min anakinra will be given half dose (i.e. 100 mg three times daily). Creatinine clearance is calculated by the Cockcroft Gault equation \[(140-age in years)/ (72 x serum creatinine in mg/dl) for men; this is multiplied by 0.85 for women.

    Treatment: Anakinra or rhIFNγ

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Personalized Immunotherapy in Sepsis: a Multicentre and Multinational, Double-blind, Double-dummy Randomized Clinical Trial
Publications
Record updated
19 March 2025